Skowronski Danuta M, De Serres Gaston, Hebert Jacques, Stark Donald, Warrington Richard, Macnabb Jane, Shadmani Ramak, Rochette Louis, MacDonald Diane, Patrick David M, Duval Bernard
UBC Centre for Disease Control, 655 West 12th Avenue, Vancouver, British Columbia, Canada V5Z 4R4.
Vaccine. 2002 Jun 21;20(21-22):2713-9. doi: 10.1016/s0264-410x(02)00214-1.
A syndrome of red eyes and respiratory symptoms was noted following receipt of influenza vaccine in Canada during the 2000-2001 influenza season. We conducted intra-dermal skin testing to determine if oculo-respiratory syndrome (ORS) was related to failure of the splitting process during vaccine manufacturing, if it was associated with a particular viral strain and to identify individuals at risk for subsequent ORS reaction. Skin testing with minute quantities of vaccine antigen induced ORS symptoms at a higher rate amongst persons previously affected by this syndrome compared to previously unaffected persons. Skin test reaction size or quality could not identify persons at risk of ORS. Skin testing could not identify a specific strain or the stage in the manufacturing process during which the trigger may have been introduced.
在2000 - 2001年流感季节期间，加拿大有报告称在接种流感疫苗后出现了红眼和呼吸道症状综合征。我们进行了皮内皮肤测试，以确定眼呼吸道综合征（ORS）是否与疫苗生产过程中的裂解过程失败有关，是否与特定病毒株相关，并识别后续发生ORS反应的风险人群。与未受该综合征影响的人相比，用微量疫苗抗原进行皮肤测试在先前受此综合征影响的人群中诱发ORS症状的发生率更高。皮肤测试反应的大小或性质无法识别有ORS风险的人群。皮肤测试无法识别引发该综合征的特定毒株或生产过程中可能引入触发因素的阶段。
